Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Revance Therapeutics
(NQ:
RVNC
)
6.585
-0.015 (-0.23%)
Streaming Delayed Price
Updated: 3:37 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Revance Therapeutics
< Previous
1
2
3
4
5
6
Next >
Analyst Ratings for Revance Therapeutics
September 09, 2022
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Needham Maintains Buy Rating for Revance Therapeutics: Here's What You Need To Know
September 09, 2022
Needham has decided to maintain its Buy rating of Revance Therapeutics (NASDAQ:RVNC) and raise its price target from $25.00 to $35.00. Shares of Revance Therapeutics are trading up 9.72% over the last...
Via
Benzinga
What 5 Analyst Ratings Have To Say About Revance Therapeutics
September 09, 2022
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
5 Analysts Have This to Say About Revance Therapeutics
September 09, 2022
Within the last quarter, Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings:
Via
Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
September 08, 2022
Via
Benzinga
AAPL Stock Alert: 13 Takeaways From the Latest Apple Event 2022
September 08, 2022
Apple (AAPL) stock is a hot topic on Thursday following the tech giant's latest event showing off new products and we've got the details!
Via
InvestorPlace
New 483 Observations Unlikely to Impact Much Awaited Revance's Daxi Approval, Says This Analyst
August 10, 2022
Via
Benzinga
Revance Therapeutics: Q2 Earnings Insights
August 09, 2022
Revance Therapeutics (NASDAQ:RVNC) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Recap: Revance Therapeutics Q1 Earnings
May 10, 2022
Revance Therapeutics (NASDAQ:RVNC) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
September 09, 2022
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to...
Via
Benzinga
Why Is Revance Therapeutics (RVNC) Stock Soaring Today?
September 08, 2022
RVNC stock is jumping 12% after the FDA approved its alternative to AbbVie's Botox. Revance's injection is supposed to last longer than Botox.
Via
InvestorPlace
Earnings Scheduled For February 28, 2022
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
September 08, 2022
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 08, 2022
Via
Benzinga
Revance Shares Shoot Higher As FDA Cleared DAXXIFY Injection For Frown Lines
September 08, 2022
The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ (NASDAQ: RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of...
Via
Benzinga
Why Asana Is Trading Higher By 24%; Here Are 24 Stocks Moving Premarket
September 08, 2022
Gainers Asana, Inc. (NYSE: ASAN) rose 24.1% to $23.62 in pre-market trading after the company reported better-than-expected results for its second quarter and issued a strong sales guidance.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 07, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
August 31, 2022
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
August 15, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Earnings Scheduled For August 9, 2022
August 09, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Via
Benzinga
Revance Therapeutics: Earnings Outlook
August 08, 2022
Revance Therapeutics (NASDAQ:RVNC) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement.
Via
Benzinga
Revance Therapeutics's Return On Capital Employed Insights
June 13, 2022
Benzinga Pro data, Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $25.26 million. Earnings fell to a loss of $64.34 million, resulting in a 1.97% decrease from last quarter.
Via
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial
April 22, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Earnings Scheduled For May 10, 2022
May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Via
Benzinga
Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Glabellar Lines
April 21, 2022
Revance Therapeutics, Inc. (NASDAQ: RVNC) announced acceptance of Biologics License Application (BLA) by the U.S. Food and Drug Administration (FDA) of its drug candidate DaxibotulinumtoxinA for...
Via
Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 21, 2022
Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value of their outstanding shares is at $49.7 million.
Via
Benzinga
Revance Therapeutics: Q4 Earnings Insights
February 28, 2022
Revance Therapeutics (NASDAQ:RVNC) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 26, 2022
Gainers Reneo Pharmaceuticals (NASDAQ:RPHM
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.